With the deadline for the FDA (US Food and Drug Administration)'s decision on Biogen's drug aducanumab fast approaching, analysts at RBC Capital Markets are less and less convinced that the result will be in Biogen's favor, writes Fiercepharma.
Aducanumab has faced many problems throughout the regulatory process. The application was turned down by an FDA expert committee in November, and the response deadline was pushed back by the agency in January.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Biomarker Operations Lead 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Communications Consultant 
Director for innovative pre-clinical testing unit 
Client Talent Acquisition Specialist 
(Senior) Drug Substance Specialist 
Production Director 
Senior Manager, Clinical Trial Budget 
2 Sales Representatives and Product Specialists 
Account Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
SAP System Specialist (Product Supply) – Business Application Services 
Clinical Trial Manager 
Quality System Manager 
Director Global Engineering 
Key Account Manager, Europe and Asia 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Nordic Medical Affairs Manager